Evidence map›Paper›PMID 38310181›Full record

ArticleAnnals of surgical oncology2024

Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative.

Nadege T Fackche, Ryan K Schmocker, Richard Nudotor, Boateng Kubi, Jordan M Cloyd, Travis E Grotz, Keith F Fournier, Sean P Dineen, Jula Veerapong, Joel M Baumgartner and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 1 country.

Nadege T FackcheDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Department of Oncologic Sciences, Morsani College of Medicine, Tampa, FL, USA.
Ryan K SchmockerDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Richard NudotorDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Boateng KubiDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Jordan M CloydDivision of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Travis E GrotzDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.
Keith F FournierDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sean P DineenDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Department of Oncologic Sciences, Morsani College of Medicine, Tampa, FL, USA.
Jula VeerapongDivision of Surgical Oncology, Department of Surgery, University of California, San Diego, CA, USA.
Joel M BaumgartnerDivision of Surgical Oncology, Department of Surgery, University of California, San Diego, CA, USA.
Callisia N ClarkeDivision of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Sameer H PatelDepartment of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Gregory C WilsonDepartment of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Laura A LambertDivision of Surgical Oncology, Department of Surgery, University of Massachusetts Medical School, Worcester, MA, USA.
Courtney PokrzywaDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI, USA.
Daniel E AbbottDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI, USA.
Byrne LeeDivision of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Charles A StaleyDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Mohammad Y ZaidiDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Fabian M JohnstonDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Jonathan B GreerDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA. jgreer13@jhmi.edu.ORCID http://orcid.org/0000-0001-8968-9710
Johns Hopkins University · USEmory University · USMoffitt Cancer Center · USUniversity of California San Diego · USUniversity of Cincinnati Medical Center · USUniversity of Wisconsin–Madison · USCity Of Hope National Medical Center · USMayo Clinic in Arizona · USMedical College of Wisconsin · USThe Ohio State University Wexner Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Massachusetts Chan Medical School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this procedure are limited. We aimed to determine the prognostic value of preoperative CEA, CA 125, and CA 19-9 on disease progression after CRS/HIPEC.

methodsPatients with CRPM treated with curative intent CRS/HIPEC from 12 participating sites in the United States from 2000 to 2017 were identified. Progression-free survival (PFS), defined as disease progression or recurrence, was the primary outcome.

resultsIn 279 patients who met inclusion criteria, the rate of disease progression was 63.8%, with a median PFS of 11 months (interquartile range [IQR] 5-20). Elevated CA 19-9 was associated with dismal PFS at 2 years (8.9% elevated vs. 30% not elevated, p < 0.01). In 113 patients who underwent upfront CRS/HIPEC, CA 19-9 emerged as the sole tumor marker independently predictive of worse PFS (hazard ratio [HR] 2.88, p = 0.048). In the subgroup of patients who had received neoadjuvant therapy (NAT), no variable was independently predictive of PFS. CA 19-9 levels over 37 U/ml were highly specific for accelerated disease progression after CRS/HIPEC. Lastly, there was no association between PFS and elevated CEA or CA 125.

conclusionsElevated CA 19-9 is associated with decreased PFS in patients with CRPM. While traditionally CEA is the main tumor marker assessed in colon cancer, we found that CA 19-9 may better inform preoperative risk stratification for poor oncologic outcomes in patients with CRPM. However, prospective studies are required to confirm this association.

Indexed as

Colorectal NeoplasmsHyperthermia, InducedPeritoneal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChemotherapy, Cancer, Regional PerfusionCombined Modality TherapyCytoreduction Surgical ProceduresDisease ProgressionHumansHyperthermic Intraperitoneal ChemotherapyRetrospective StudiesSurvival RateBiomarkers, Tumor

Identifiers

PMID38310181
OpenAlexW4391515600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.